To assess pertuzumab plus trastuzumab and an aromatase inhibitor (AI) in patients with human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive metastatic/locally advanced breast cancer (MBC/LABC).
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial / Rimawi, M., Ferrero, J., de la Haba-Rodriguez, J., Poole, C., De Placido, S., Osborne, C.K., Hegg, R., Easton, V., Wohlfarth, C., Arpino, G.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 1527-7755. - 36:28(2018), pp. 2826-2835. [10.1200/JCO.2017.76.7863]
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial
De Placido, Sabino;Arpino, Grazia
2018
Abstract
To assess pertuzumab plus trastuzumab and an aromatase inhibitor (AI) in patients with human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive metastatic/locally advanced breast cancer (MBC/LABC).| File | Dimensione | Formato | |
|---|---|---|---|
|
jco.2017.76.7863.pdf
non disponibili
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
1.35 MB
Formato
Adobe PDF
|
1.35 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
